Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCapital LeasesCash & Current InvestmentsCash & EquivalentsCommon EquityConvertible DebtCurrent AssetsCurrent Deferred RevenueCurrent LeasesGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityMinority InterestNon-Current AssetsNon-Current DebtNon-Current Deffered RevenueNotes PayablesOperating LeasesOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShares OutstandingShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Volitionrx (VNRX) Payables (2018 - 2025)

Volitionrx filings provide 11 years of Payables readings, the most recent being $5.3 million for Q4 2025.

  • On a quarterly basis, Payables rose 92.94% to $5.3 million in Q4 2025 year-over-year; TTM through Dec 2025 was $5.3 million, a 92.94% increase, with the full-year FY2025 number at $5.3 million, up 92.94% from a year prior.
  • Payables hit $5.3 million in Q4 2025 for Volitionrx, up from $4.6 million in the prior quarter.
  • In the past five years, Payables ranged from a high of $5.3 million in Q4 2025 to a low of $1.1 million in Q2 2021.
  • Median Payables over the past 5 years was $3.0 million (2023), compared with a mean of $2.9 million.
  • Biggest five-year swings in Payables: soared 140.24% in 2022 and later dropped 24.8% in 2025.
  • Volitionrx's Payables stood at $1.5 million in 2021, then surged by 97.28% to $3.0 million in 2022, then increased by 5.53% to $3.2 million in 2023, then dropped by 13.86% to $2.8 million in 2024, then soared by 92.94% to $5.3 million in 2025.
  • The last three reported values for Payables were $5.3 million (Q4 2025), $4.6 million (Q3 2025), and $2.5 million (Q2 2025) per Business Quant data.